Skip to main content
. 2022 Jul 1;7(4):100517. doi: 10.1016/j.esmoop.2022.100517

Figure 2.

Figure 2

Change from baseline for EORTCQLQ-OES18scores at week 12 and week 18. EORTC QLQ-OES18, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Cancer Module 18 items; ICC, investigator-chosen chemotherapy; LS, least square; n, patients with baseline and at least one post-baseline measurement; TIS, tislelizumab.